

10/649,236

=> file caplus

FILE 'CAPLUS' ENTERED AT 15:49:24 ON 29 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 29 Apr 2004 VOL 140 ISS 18

FILE LAST UPDATED: 28 Apr 2004 (20040428/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 54 SEA FILE=REGISTRY SSS FUL L1

L4 3 SEA FILE=CAPLUS L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN


ACCESSION NUMBER: 2004:203834 CAPLUS

DOCUMENT NUMBER: 140:235722

TITLE: Preparation of 6-[4-(di- or trifluorophenyl)oxazol-5-

yl][1,2,4]triazolo[4,3-a]pyridine as inhibitors of
mitogen-activated protein (MAP) kinases
INVENTOR(S): Dombroski, Mark Anthony; Letavic, Michael Anthony;
McClure, Kim Francis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020440	A1	20040311	WO 2003-IB3847	20030819
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004053958	A1	20040318	US 2003-649236	20030827
PRIORITY APPLN. INFO.:			US 2002-407177P	P 20020830
OTHER SOURCE(S):		MARPAT 140:235722		
GI				



I

AB The present invention relates to novel triazolo-pyridines of the formula (I) [wherein R1 is fluoro; m = 2,3; R2 is C3-6 cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-4 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; or R2 is C1-6 alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, C1-6 alkyl, hydroxy, C1-6 alkoxy and C1-6 alkyl-CO-O; with the proviso that said compd. of this formula cannot be 6-[4-(2,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine or 6-[4-(3,4-difluorophenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine] or

pharmaceutically acceptable salt thereof; to intermediates for their prepn., and to pharmaceutical compns. contg. them and to their medicinal use. The compds. I are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, a mixt. of [.alpha.-(p-toluenesulfonyl)-2,6-difluorobenzyl]isonitrile (1.79 g, 5.84 mmol), 3-isopropyl-[1,2,4]triazolo[4,3-a]-6-pyridinecarboxaldehyde > (1.10 g, 5.84 mmol), potassium carbonate (1.05 g, 7.59 mmol) and acetonitrile (17.5 mL) was refluxed for 22 h to give, after workup and silica gel chromatog., 6-[4-(2,6-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine as a yellow solid. A tablet formulation contg. 6-[4-(2,5-difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine was prepd., which can be administered to a human from one to four times a day for inhibiting cartilage damage or treating osteoarthritis.


IT 668981-02-0P

RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(X-ray crystallog. data and polymorphism; prepn. of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668981-02-0 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 668990-79-2P, 3-Cyclopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate; prepn. of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)


RN 668990-79-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




IT 668981-03-1P, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-
 [1,2,4]triazolo[4,3-a]pyridine 668981-04-2P,
 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-
 a]pyridine hydrochloride 668981-05-3P, 6-[4-(2,5-
 Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
 methanesulfonate 668981-06-4P, 6-[4-(2,5-Difluorophenyl)oxazol-5-
 yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate
 668981-07-5P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-
 [1,2,4]triazolo[4,3-a]pyridine sulfate 668990-77-0P,
 3-tert-Butyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-
 a]pyridine 668990-78-1P, 3-tert-Butyl-6-[4-(2,4-
 difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
 668990-83-8P, 3-Cyclopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-
 yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-84-9P,
 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-
 [1,2,4]triazolo[4,3-a]pyridine 668990-85-0P,
 6-[4-(2,4-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-
 [1,2,4]triazolo[4,3-a]pyridine 668990-86-1P,
 3-Cyclobutyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-
 a]pyridine 668990-87-2P, 3-Isopropyl-6-[4-(2,4,5-
 trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
 668990-90-7P, 3-Isopropyl-6-[4-(2,3,4-trifluorophenyl)oxazol-5-
 yl]-[1,2,4]triazolo[4,3-a]pyridine 668990-91-8P,
 3-Isopropyl-6-[4-(2,3,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-
 a]pyridine 668990-92-9P, 3-Isopropyl-6-[4-(2,4,6-
 trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
 668990-93-0P, 3-Isopropyl-6-[4-(3,4,5-trifluorophenyl)oxazol-5-yl]-
 [1,2,4]triazolo[4,3-a]pyridine 668990-94-1P,
 3-tert-Butyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-
 a]pyridine 668990-95-2P, 3-Cyclopropyl-6-[4-(2,4,5-
 trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
 668990-96-3P, 3-(1-Methylcyclopropyl)-6-[4-(2,4,5-
 trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
 668990-97-4P, 3-Isopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-
 yl]-[1,2,4]triazolo[4,3-a]pyridine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38
 kinase inhibitors and therapeutic agents)
 RN 668981-03-1 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-
 methylethyl)- (9CI) (CA INDEX NAME)

10/649,236



RN 668981-04-2 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 668981-05-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:203832 CAPLUS

DOCUMENT NUMBER: 140:235721

TITLE: Novel processes and intermediates for preparing [1,2,4]triazolo[4,3-a]pyridines

INVENTOR(S): Buzon, Richard Allen Sr.; Castaldi, Michael James; Li, Zhengong Bryan; Ripin, David Harold Brown; Tao, Yong

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020438	A2	20040311	WO 2003-IB3669	20030818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2004053959 A1 20040318 US 2003-649247 20030827

PRIORITY APPLN. INFO.: US 2002-407085P P 20020830


OTHER SOURCE(S): CASREACT 140:235721; MARPAT 140:235721

GI




AB The present invention relates and intermediates to a novel process for prepg. triazolo-pyridines of the formula (I) [$R^1 = H$, cyano, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, Ph, C1-10 heteroaryl, C1-10 heterocyclyl or NH_2 ; $R^3 =$ halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, perhalo-C1-6 alkyl, Ph, C1-10 heteroaryl, C1-10 heterocyclyl, C3-10 cycloalkyl, HO, C1-6 alkoxy, perhalo-C1-10 alkoxy, PhO, C1-10 heteroaryloxy, C1-10 heterocycliloxy-C3-10 cycloalkyloxy, C1-6 alkylthio, C1-16 alkylsulfonyl, C1-6 alkylsulfamoyl, amino, mono - or di(C1-6 alkyl)amino, C1-6 sulfonylamino, C1-6 alkyl-carbonylamino, etc.; or two adjacent R^2 taken together with the carbon atoms to which they are attached to form a five to six membered carbocyclic or heterocyclic ring; $m =$ an integer from 0-5; $R^4 = H$, F, Cl, $R^5-B-(CH_2)_n-$; $n =$ an integer from 0-6; B = a bond, (CHR6), O, S, SO_2 , CO, O-CO, CO-O, CO-NR6, R6N, R6NSO2, R6NCO, SO_2NR_6 , R6NCONR7, O-CONR6 or R6NCO-O; $R^5 = H$, CF_3 , cyano, each (un)substituted Ph, C1-10 heterocyclyl, C1-10 heteroaryl, or C3-10 cycloalkyl, etc.; $R^6 = H$, C1-6 alkylsulfonyl, C1-6 alkyl] or acceptable salts thereof, e.g., comprising reacting 6-(oxazol-5-yl)[1,2,4]triazolo[4,3-a]pyridines (II) ($L =$ a leaving group and R^1 and R^4 are as defined above) with phenylboronic acids (III) and a transition metal catalyst. The compds. I prepd. by the methods of the present invention are potent inhibitors of mitogen-activated protein (MAP) kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Thus, 6-(4-bromooxazol-5-yl)-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine (33.0 g, 0.107 mol), 2,5-difluorophenylboronic acid (25.34 g, 0.1605 mol), $Pd(PPh_3)_4$ (12.36 g, 0.0107 mol), Et_3N (22.37 mL, 0.1605 mol), 2B ethanol (495 mL), and water (33 mL), were added to a 2 L 4 neck round bottom flask (equipped with mech. stirring, nitrogen, heating mantle, temp. controller, and a condenser), stirred while heating to 65 to 70.degree., and kept stirring overnight at .apprx.70.degree.. Two addnl. difluorophenylboronic acid (8.5 g, 0.054 mol) and Et_3N (7.53 mL, 0.054 mol), were added and each time the reaction was allowed to proceed overnight at 70.degree.. Toluene (30 mL) was added and the reaction was allowed to go overnight once again at 70.degree., treated with H_2O (495 mL), and pot-granulated for 4 h at 20 to 25.degree.. The solids were collected by vacuum filtration, washed with 2B ethanol/ H_2O (50:50) (25 mL of each), and dried in a vacuum oven at 45.degree. for 4 ho under full vacuum to afford 14.4 g 3-isopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine (40.6% yield, 93.4% purity by HPLC).

IT **668981-02-0P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine deriv. or cyclocondensation of .alpha.-tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)
 RN 668981-02-0 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT **668981-03-1P**, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **668981-04-2P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride **668981-05-3P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate **668981-06-4P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate **668981-07-5P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine deriv. or cyclocondensation of .alpha.-tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)
 RN 668981-03-1 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 668981-04-2 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

10/649,236



● HCl


RN 668981-05-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 668981-06-4 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0

10/649,236


CMF C18 H14 F2 N4 O



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 668981-07-5 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O



CM 2


CRN 7664-93-9

CMF H2 O4 S



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:716275 CAPLUS
 DOCUMENT NUMBER: 137:232658
 TITLE: Preparation of 6-(phenylheterocyclyl)-
 [1,2,4]triazolo[4,3-a]pyridines as anti-inflammatory
 agents
 INVENTOR(S): Dombroski, Mark Anthony; Duplantier, Allen Jacob;
 Laird, Ellen Ruth; Letavic, Michael Anthony; McClure,
 Kim Francis
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 111 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072579	A1	20020919	WO 2002-IB424	20020208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1370559	A1	20031217	EP 2002-710260	20020208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300437	A	20040216	EE 2003-437	20020208
US 2003096838	A1	20030522	US 2002-94760	20020311
US 6696464	B2	20040224		
NO 2003003969	A	20031013	NO 2003-3969	20030908
PRIORITY APPLN. INFO.:				
			US 2001-274840P	P 20010309
			WO 2002-IB424	W 20020208
OTHER SOURCE(S): MARPAT 137:232658				
GI				



AB Title compds. I [wherein Het = (un)substituted pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl; R2 = H, alkenyl, alkynyl, or (un)substituted (cyclo)alkyl, Ph, heteroaryl, or heterocyclyl, or amino; R3 = halo, (cyclo)alkyl(oxy), (perhalo)alkyl, alkenyl, alkynyl, Ph, heteroaryl(oxy), heterocyclyl(oxy), OH, (perhalo)alkoxy, PhO, alkylthio, alkylsulfonyl, alkylaminosulfonyl, NO2, (un)substituted amino, carbamoyl, etc.; n = 0-5; or pharmaceutically acceptable salts thereof] were prepd. as potent inhibitors of MAP kinases, preferably p38 kinase (no data). For example, 6-chloronicotinic acid was condensed with N,O-dimethylhydroxylamine.bul.HCl (96%). Treatment of the amide with (i-Bu)2AlH gave the aldehyde (24%), which was coupled with (phenyl) (p-tolylsulfonyl)methylisocyanide to afford 2-chloro-5-(4-phenyloxazol-5-yl)pyridine (71%). Conversion to the hydrazine (100%), followed by coupling with isobutyryl chloride and cyclization using POCl3 (32%), produced II. I are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases, and other disorders (no data).

IT **459447-61-1P**, 3-Isopropyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-64-4P**, 3-Ethyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-66-6P**, 3-Cyclopropyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-67-7P**, 3-Cyclobutyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-69-9P**, 3-Difluoromethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-71-3P**, 3-(Isoxazol-5-yl)-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-72-4P**, 6-(4-Phenyloxazol-5-yl)-3-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyridine **459447-73-5P**, 3-Cyclobutyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-74-6P**, 3-Cyclopropyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-75-7P**, 3-Ethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-76-8P**, 3-Ethyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-77-9P**, 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-78-0P**, 3-Cyclobutyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-79-1P**, 3-Isopropyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-80-4P**, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-82-6P**, 3-Cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-83-7P**, 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine **459447-84-8P**, 3-Isopropyl-6-(2-methyl-4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-88-2P**, 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-89-3P**, [6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-yl]acetic acid ethyl ester **459447-90-6P**, 3-(2-Chlorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-


[1,2,4]triazol[4,3-a]pyridine **459447-91-7P**, 6-[4-(2-Fluoro-5-methylphenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-92-8P** **459447-93-9P**, 3-(2-Fluorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-94-0P**, [6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-yl]dimethylamine **459447-95-1P**, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine **459447-96-2P**, 6-[4-(3-Chloro-4-fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459447-97-3P**, 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459447-98-4P**, 3-(2-Chlorophenyl)-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459448-00-1P**, 6-[4-(3,4-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459448-01-2P**, 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine **459448-02-3P**, 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anti-inflammatory agent; prepn. of (phenylheterocyclyl)triazolopyridines as anti-inflammatory agents)


RN 459447-61-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(4-phenyl-5-oxazolyl)-(9CI) (CA INDEX NAME)



RN 459447-64-4 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-[4-(3-methylphenyl)-5-oxazolyl]-(9CI) (CA INDEX NAME)



RN 459447-66-6 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(4-fluorophenyl)-5-oxazolyl]-(9CI) (CA INDEX NAME)

10/649,236




RN 459447-67-7 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-69-9 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(difluoromethyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-71-3 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(5-isoxazolyl)-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)

10/649,236




RN 459447-72-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-(4-phenyl-5-oxazolyl)-3-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 459447-73-5 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-(4-phenyl-5-oxazolyl)- (9CI)
(CA INDEX NAME)



RN 459447-74-6 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 459447-75-7 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-(4-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)

10/649,236




RN 459447-76-8 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-[4-(4-fluorophenyl)-5-oxazolyl]-
(9CI) (CA INDEX NAME)



RN 459447-77-9 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(1-
methylethyl)- (9CI) (CA INDEX NAME)



RN 459447-78-0 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclobutyl-6-[4-(3-methylphenyl)-5-
oxazolyl]- (9CI) (CA INDEX NAME)

10/649,236




RN 459447-79-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-80-4 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459447-82-6 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

10/649,236




RN 459447-83-7 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-phenyl-
(9CI) (CA INDEX NAME)



RN 459447-84-8 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(2-methyl-4-phenyl-5-oxazolyl)-
(9CI) (CA INDEX NAME)



RN 459447-88-2 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-
3-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/649,236




RN 459447-89-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine-3-acetic acid, 6-[4-(4-fluorophenyl)-5-oxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 459447-90-6 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-91-7 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2-fluoro-5-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)

10/649,236




RN 459447-92-8 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 459447-93-9 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-fluorophenyl)-6-[4-(3-methylphenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459447-94-0 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridin-3-amine, 6-[4-(4-fluorophenyl)-5-oxazolyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

10/649,236




RN 459447-95-1 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluoro-3-methylphenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 459447-96-2 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-chloro-4-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459447-97-3 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/649,236




RN 459447-98-4 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459448-00-1 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459448-01-2 CAPLUS


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)

10/649,236



RN 459448-02-3 CAPLUS

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-phenyl-
(9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file uspatall

FILE 'USPATFULL' ENTERED AT 15:50:15 ON 29 APR 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:50:15 ON 29 APR 2004


CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que

L1

STR

10/649,236



Structure attributes must be viewed using STN Express query preparation.

L3 54 SEA FILE=REGISTRY SSS FUL L1
L5 4 SEA L3

=> d l5 1-4 ibib abs hitstr

L5 ANSWER 1 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:70731 USPATFULL

TITLE: Novel processes and intermediates for preparing triazolo-pyridines

INVENTOR(S): Buzon, Richard A., SR., Stonington, CT, UNITED STATES
Castaldi, Michael J., Pawcatuck, CT, UNITED STATES
Li, Zhengong B., East Lyme, CT, UNITED STATES
Ripin, David H. B., Old Saybrook, CT, UNITED STATES
Tao, Yong, Salem, CT, UNITED STATES

PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053959	A1	20040318
APPLICATION INFO.:	US 2003-649247	A1	20030827 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-WO40243	20000713
	WO 2000-WO63204	20001026
	WO 2000-WO31065	20000602
	WO 2000-WO6563	20000210
	WO 2000-WO41698	20000720
	US 2002-407085P	20020830 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49,
NEW YORK, NY, 10017-5612

NUMBER OF CLAIMS: 48

EXEMPLARY CLAIM: 1

LINE COUNT: 3578

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates and intermediates to a novel process for preparing triazolo-pyridines of the formula I ##STR1##

wherein R.sup.1 is selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl or other suitable substituents;

R.sup.3 is selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl or other suitable substituents;

s is an integer from 0-5;

R.sup.4 is hydrogen or a suitable substituent and to intermediates for their preparation. The compounds prepared by the methods of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **668981-02-0P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine

(prepn. of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine deriv. or cyclocondensation of .alpha.-tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

RN 668981-02-0 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **668981-03-1P**, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **668981-04-2P**,


6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine hydrochloride **668981-05-3P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine methanesulfonate **668981-06-4P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate **668981-07-5P**, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine sulfate

(prepn. of triazolopyridines as p38 kinase inhibitors by Suzuki coupling of phenylboronic acid with (bromooxazolyl)triazolopyridine deriv. or cyclocondensation of .alpha.-tosylbenzyl isonitrile with triazolopyridinecarboxaldehyde)

RN 668981-03-1 USPATFULL


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/649,236



RN 668981-04-2 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 668981-05-3 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0

CMF C18 H14 F2 N4 O




CM 2

CRN 75-75-2

CMF C H4 O3 S

10/649,236




RN 668981-06-4 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0


CMF C18 H14 F2 N4 O



CM 2

CRN 104-15-4

CMF C7 H8 O3 S



RN 668981-07-5 USPATFULL


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 668981-02-0

CMF C18 H14 F2 N4 O


10/649,236



CM 2

CRN 7664-93-9

CMF H2 O4 S



L5 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:70730 USPATFULL

TITLE: Di and trifluoro-triazolo-pyridines anti-inflammatory compounds

INVENTOR(S): Dombroski, Mark A., Waterford, CT, UNITED STATES
Letavic, Michael A., Mystic, CT, UNITED STATES

PATENT ASSIGNEE(S): McClure, Kim F., Mystic, CT, UNITED STATES
Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053958	A1	20040318
APPLICATION INFO.:	US 2003-649236	A1	20030827 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-407177P	20020830 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	

NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 3038

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel triazolo-pyridines of the formula
I ##STR1##

wherein R^{sup.1} is fluoro;

s is an integer from two to three;

R^{sup.2} is (C₃₋₆)cycloalkyl optionally substituted by one or

two moieties independently selected from the group consisting of halo, (C.sub.1-C.sub.4)alkyl, hydroxy, (C.sub.1-C.sub.6)alkoxy and (C.sub.1-C.sub.6)alkyl-(C.dbd.O)--O--;

or R.sup.2 is (C.sub.1-C.sub.6)alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C.sub.1-C.sub.6)alkyl, hydroxy, (C.sub.1-C.sub.6)alkoxy and (C.sub.1-C.sub.6)alkyl-(C.dbd.O)--O--;

with the proviso that said compound of formula I cannot be

6-[4-(2,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; or

6-[4-(3,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine;

to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **668981-02-0P**

(X-ray crystallog. data and polymorphism; prepn. of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668981-02-0 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,5-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT **668990-79-2P**, 3-Cyclopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine


(intermediate; prepn. of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38 kinase inhibitors and therapeutic agents)

RN 668990-79-2 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-cyclopropyl-6-[4-(2,4-difluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



- IT **668981-03-1P**, 6-[4-(2,6-Difluorophenyl)oxazol-5-yl]-3-isopropyl-
 [1,2,4]triazolo[4,3-a]pyridine **668981-04-2P**,
 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-
 a]pyridine hydrochloride **668981-05-3P**, 6-[4-(2,5-
 Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine
 methanesulfonate **668981-06-4P**, 6-[4-(2,5-Difluorophenyl)oxazol-
 5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine p-toluenesulfonate
668981-07-5P, 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-isopropyl-
 [1,2,4]triazolo[4,3-a]pyridine sulfate **668990-77-0P**,
 3-tert-Butyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-
 a]pyridine **668990-78-1P**, 3-tert-Butyl-6-[4-(2,4-
 difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
668990-83-8P, 3-Cyclopropyl-6-[4-(2,5-difluorophenyl)oxazol-5-
 yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-84-9P**,
 6-[4-(2,5-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-
 [1,2,4]triazolo[4,3-a]pyridine **668990-85-0P**,
 6-[4-(2,4-Difluorophenyl)oxazol-5-yl]-3-(1-methylcyclopropyl)-
 [1,2,4]triazolo[4,3-a]pyridine **668990-86-1P**,
 3-Cyclobutyl-6-[4-(2,5-difluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-
 a]pyridine **668990-87-2P**, 3-Isopropyl-6-[4-(2,4,5-
 trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
668990-90-7P, 3-Isopropyl-6-[4-(2,3,4-trifluorophenyl)oxazol-5-
 yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-91-8P**,
 3-Isopropyl-6-[4-(2,3,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-
 a]pyridine **668990-92-9P**, 3-Isopropyl-6-[4-(2,4,6-
 trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
668990-93-0P, 3-Isopropyl-6-[4-(3,4,5-trifluorophenyl)oxazol-5-
 yl]-[1,2,4]triazolo[4,3-a]pyridine **668990-94-1P**,
 3-tert-Butyl-6-[4-(2,4,5-trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-
 a]pyridine **668990-95-2P**, 3-Cyclopropyl-6-[4-(2,4,5-
 trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
668990-96-3P, 3-(1-Methylcyclopropyl)-6-[4-(2,4,5-
 trifluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine
668990-97-4P, 3-Isopropyl-6-[4-(2,4-difluorophenyl)oxazol-5-
 yl]-[1,2,4]triazolo[4,3-a]pyridine
 (prepn. of [(di- and trifluorophenyl)oxazolyl]triazolopyridine as p38
 kinase inhibitors and therapeutic agents)
- RN **668981-03-1** USPATFULL
- CN **1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(2,6-difluorophenyl)-5-oxazolyl]-3-(1-
 methylethyl)- (9CI) (CA INDEX NAME)**



L5 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2003:140996 USPATFULL

TITLE: Novel triazolo-pyridines anti-inflammatory compounds

INVENTOR(S): McClure, Kim F., Mystic, CT, UNITED STATES

Letavic, Michael A., Mystic, CT, UNITED STATES

Dombroski, Mark A., Waterford, CT, UNITED STATES

Duplantier, Allen J., Ledyard, CT, UNITED STATES

Laird, Ellen R., Longmont, CO, UNITED STATES

PATENT ASSIGNEE(S): Pfizer Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096838	A1	20030522
	US 6696464	B2	20040224
APPLICATION INFO.:	US 2002-94760	A1	20020311 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-274840P	20010309 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	
NUMBER OF CLAIMS:	57	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5372	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel triazolo-pyridines of the formula
I ##STR1##

wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen;

R.sup.2 is selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl or other suitable substituents;

R.sup.3 is selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl or other suitable substituents;

s is an integer from 0-5;

to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis,

rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 459447-61-1P, 3-Isopropyl-6-(4-phenyloxazol-5-yl)-
 [1,2,4]triazolo[4,3-a]pyridine 459447-64-4P,
 3-Ethyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
 459447-66-6P, 3-Cyclopropyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-
 [1,2,4]triazolo[4,3-a]pyridine 459447-67-7P,
 3-Cyclobutyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]
 pyridine 459447-69-9P, 3-Difluoromethyl-6-(4-phenyloxazol-5-
 yl)-[1,2,4]triazolo[4,3-a]pyridine 459447-71-3P,
 3-(Isoxazol-5-yl)-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
 459447-72-4P, 6-(4-Phenyloxazol-5-yl)-3-(2,2,2-trifluoroethyl)-
 [1,2,4]triazolo[4,3-a]pyridine 459447-73-5P,
 3-Cyclobutyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
 459447-74-6P, 3-Cyclopropyl-6-(4-phenyloxazol-5-yl)-
 [1,2,4]triazolo[4,3-a]pyridine 459447-75-7P,
 3-Ethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
 459447-76-8P, 3-Ethyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-
 [1,2,4]triazolo[4,3-a]pyridine 459447-77-9P,
 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]
 pyridine 459447-78-0P, 3-Cyclobutyl-6-(4-m-tolyloxazol-5-yl)-
 [1,2,4]triazolo[4,3-a]pyridine 459447-79-1P,
 3-Isopropyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine
 459447-80-4P, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-
 isopropyl-[1,2,4]triazolo[4,3-a]pyridine 459447-82-6P,
 3-Cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)oxazol-5-yl]-
 [1,2,4]triazolo[4,3-a]pyridine 459447-83-7P,
 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine
 459447-84-8P, 3-Isopropyl-6-(2-methyl-4-phenyloxazol-5-yl)-
 [1,2,4]triazolo[4,3-a]pyridine 459447-88-2P,
 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-isopropyl-
 [1,2,4]triazolo[4,3-a]pyridine 459447-89-3P,
 [6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-
 yl]acetic acid ethyl ester 459447-90-6P, 3-(2-Chlorophenyl)-6-
 [4-(m-tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine
 459447-91-7P, 6-[4-(2-Fluoro-5-methylphenyl)oxazol-5-yl]-
 [1,2,4]triazol[4,3-a]pyridine 459447-92-8P 459447-93-9P
 , 3-(2-Fluorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]
 pyridine 459447-94-0P, [6-[4-(4-Fluorophenyl)oxazol-5-yl]-
 [1,2,4]triazol[4,3-a]pyridin-3-yl]dimethylamine 459447-95-1P,
 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]
 pyridine 459447-96-2P, 6-[4-(3-Chloro-4-fluorophenyl)oxazol-5-
 yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine 459447-97-3P,
 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]
 pyridine 459447-98-4P, 3-(2-Chlorophenyl)-6-[4-(4-
 fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine
 459448-00-1P, 6-[4-(3,4-Difluorophenyl)oxazol-5-yl]-3-isopropyl-
 [1,2,4]triazol[4,3-a]pyridine 459448-01-2P,
 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]
 pyridine 459448-02-3P, 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-
 phenyl-[1,2,4]triazol[4,3-a]pyridine
 (anti-inflammatory agent; prepn. of (phenylheterocyclyl)triazolopyridin
 es as anti-inflammatory agents)

RN 459447-61-1 USPATFULL


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(4-phenyl-5-oxazolyl)-
 (9CI) (CA INDEX NAME)

10/649,236




RN 459447-97-3 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459447-98-4 USPATFULL


CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459448-00-1 USPATFULL


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/649,236




RN 459448-01-2 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 459448-02-3 USPATFULL

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 4 USPAT2 on STN

ACCESSION NUMBER: 2003:140996 USPAT2

TITLE: Triazolo-pyridines anti-inflammatory compounds

INVENTOR(S): McClure, Kim F., Mystic, CT, United States

Letavic, Michael A., Mystic, CT, United States

Dombroski, Mark A., Waterford, CT, United States

Duplantier, Allen J., Ledyard, CT, United States

Laird, Ellen R., Longmont, CO, United States

PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6696464	B2	20040224
APPLICATION INFO.:	US 2002-94760		20020311 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-274840P	20010309 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Seaman, D. Margaret	
LEGAL REPRESENTATIVE:	Richardson, Peter C., Butterfield, Garth	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	5301	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel triazolo-pyridines of the formula
I ##STR1##

wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen;

R.sup.2 is selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl or other suitable substituents;

R.sup.3 is selected from the group consisting of hydrogen, (C.sub.1-C.sub.6)alkyl or other suitable substituents;

s is an integer from 0-5;

to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **459447-61-1P**, 3-Isopropyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-64-4P**, 3-Ethyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-66-6P**, 3-Cyclopropyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-67-7P**, 3-Cyclobutyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-69-9P**, 3-Difluoromethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-71-3P**, 3-(Isoxazol-5-yl)-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-72-4P**, 6-(4-Phenyloxazol-5-yl)-3-(2,2,2-trifluoroethyl)-[1,2,4]triazolo[4,3-a]pyridine **459447-73-5P**, 3-Cyclobutyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-74-6P**, 3-Cyclopropyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-75-7P**, 3-Ethyl-6-(4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-76-8P**, 3-Ethyl-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-77-9P**, 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-78-0P**, 3-Cyclobutyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-79-1P**, 3-Isopropyl-6-(4-m-tolyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine

459447-80-4P, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine **459447-82-6P**,
 3-Cyclopropyl-6-[4-(4-fluoro-3-methylphenyl)oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine **459447-83-7P**,
 6-[4-(4-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine **459447-84-8P**, 3-Isopropyl-6-(2-methyl-4-phenyloxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridine **459447-88-2P**,
 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]-pyridine **459447-89-3P**,
 [6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-yl]acetic acid ethyl ester **459447-90-6P**,
 3-(2-Chlorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-91-7P**, 6-[4-(2-Fluoro-5-methylphenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-92-8P**
459447-93-9P, 3-(2-Fluorophenyl)-6-[4-(m-tolyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459447-94-0P**,
 [6-[4-(4-Fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridin-3-yl]dimethylamine **459447-95-1P**, 6-[4-(4-Fluoro-3-methylphenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine **459447-96-2P**,
 6-[4-(3-Chloro-4-fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459447-97-3P**,
 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459447-98-4P**, 3-(2-Chlorophenyl)-6-[4-(4-fluorophenyl)oxazol-5-yl]-[1,2,4]triazol[4,3-a]pyridine **459448-00-1P**,
 6-[4-(3,4-Difluorophenyl)oxazol-5-yl]-3-isopropyl-[1,2,4]triazol[4,3-a]pyridine **459448-01-2P**,
 6-[4-(4-Fluorophenyl)-2-methyloxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine **459448-02-3P**, 6-[4-(3-Fluorophenyl)oxazol-5-yl]-3-phenyl-[1,2,4]triazol[4,3-a]pyridine
 (anti-inflammatory agent; prepn. of (phenylheterocyclyl)triazolopyridines as anti-inflammatory agents)


RN 459447-61-1 USPAT2

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(1-methylethyl)-6-(4-phenyl-5-oxazolyl)-(9CI) (CA INDEX NAME)




RN 459447-64-4 USPAT2

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-ethyl-6-[4-(3-methylphenyl)-5-oxazolyl]-(9CI) (CA INDEX NAME)




10/649,236




RN 459447-98-4 USPAT2

CN 1,2,4-Triazolo[4,3-a]pyridine, 3-(2-chlorophenyl)-6-[4-(4-fluorophenyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)



RN 459448-00-1 USPAT2


CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3,4-difluorophenyl)-5-oxazolyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 459448-01-2 USPAT2

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(4-fluorophenyl)-2-methyl-5-oxazolyl]-3-phenyl- (9CI) (CA INDEX NAME)

10/649,236



RN 459448-02-3 USPAT2

CN 1,2,4-Triazolo[4,3-a]pyridine, 6-[4-(3-fluorophenyl)-5-oxazolyl]-3-phenyl-
(9CI) (CA INDEX NAME)

